




3rd ICPO FORUM for Theranostics in Precision Oncology

12–13 October 2023 · Science Congress Center
Garching Munich · Germany





*Greetings to all participants of the 3rd ICPO Forum for
Theranostics in Precision Oncology being held physical in Munich,
Germany, on October 12th and 13th, 2023*

**Dear friends, supporters, and valued partners
of the ICPO Foundation,**


We would like to warmly welcome all of you attending the 3rd edition of the ICPO Forum for Theranostics in Precision Oncology from around the world. We are honored to have participants joining us from India, China, Middle East, the US, Canada, and other locations around the globe, while more than 18 industry sponsors are kindly supporting the event.

The goal of the ICPO Forum is to connect participants across all horizons, including industry, academia, as well as medical and patient societies, associations, foundations, investors, and philanthropists. Thank you thus for joining us on October 12 and 13 and making our 3rd ICPO Forum a lively and memorable event.

By attending the ICPO Forum, one recognizes the Paradigm Shift to Precision Oncology and lives up to its promises: earlier, more accurate diagnosis, more informed and involved patients, better predictable outcomes, low side-effects, sustainable health economics, and longer survival with preserved quality of life. Ultimately, the ICPO Foundation brings its Community together and thrives to fulfill its mission to accelerate the paradigm shift in Oncology by implementing a more effective patient-centered focus around new Radio Theranostics technologies, this to all patients in need irrespectively of race, country, social status and all else.

The program of the 3rd ICPO Forum has been designed to encompass different viewpoints in order to understand and shape the future growth of Radio Theranostics together. After official addresses, the stage will be set with keynote lectures by world-class nuclear medicine and oncology experts from Germany (Professor Dr. Richard P. Baum and Professor Dr. Matthias Eiber), Australia (Professor Dr. Andrew Scott) and USA (Professor Dr. Oliver Sartor). In the first sessions, the ICPO Foundation will then officially launch its ICPO Academy and present an overview of international certified centers initiatives, including the development of the ICPO Centers network. The following sessions will be articulated around efforts towards increased patient access, innovation and technology advances, supply chain scale up and delivery of radiopharmaceuticals up to the bedside. The Forum sessions will be complemented by constructive





multidisciplinary panel discussions aimed at opening new avenues to critical global issues for patient care today in the field of Radiomolecular Precision Oncology. Moreover, the award ceremony of the 2nd Maurits W. Geerlings Next Generation Award for Outstanding Research and Contributions to Actinium-225 Radiopharmaceuticals will take place during the ICPO Forum.

With its 3rd Forum edition, the ICPO stands more than ever for its mission to support the community, science, training, and expansion of patient access worldwide in Precision Oncology in an inclusive and collaborative approach!

The ICPO Board of Trustees and the entire ICPO team are honored to host you at the ICPO Forum. We hope you will enjoy your time and interact with expert speakers and panelists to experience a rich and unique Forum and being part of the ICPO community.

In the future we look forward to meeting you again at the upcoming ICPO events and in 2025 for the 4th ICPO Forum for Theranostics in Precision Oncology! In the meantime, would you like to support the ICPO activities by making a donation or becoming a member of the ICPO Foundation, please find all valuable information on our website www.icpo.foundation.

Sincerely,

**Sen. HC
Udo J. Vetter**

Chairman of the
ICPO Forum and
ICPO Board of Trustees

**Prof. Dr.
Richard P. Baum**

Chairman of the
ICPO Scientific Advisory
Board and President of
the ICPO Academy

Odile Jaume

CEO of the
ICPO Foundation

PROGRAM

Subject to change | Revision **October 12, 2023** |
All stated times correspond to CENTRAL EUROPEAN TIME

THURSDAY, 12 OCTOBER 2023

Collaborative efforts to greater patient access to Radio Theranostics

07:30 – 08:30	Registration and Coffee
08:30 – 08:33	Welcome address from the ICPO Foundation Chairman Udo J. Vetter, Germany
08:33 – 08:36	Welcome address from the Bavarian Minister of State Florian Herrmann, Germany
08:36 – 08:39	Welcome address from WARMTH President Mike Sathekge, South Africa
08:39 – 08:42	Welcome words and Scientific Programme Richard P. Baum, Germany
08:36 – 08:39	Welcome words and Keynote Lectures Odile Jaume, Germany

SESSION I: Keynote lectures

08:45 – 09:05	Importance of real-world evidence for Radiomolecular Theranostics patients Andrew M. Scott, Australia
09:05 – 09:25	Radiomolecular Theranostics amongst Precision Oncology options Oliver Sartor, USA
09:25 – 09:45	PSMA Theranostics: Ongoing game changing innovations for prostate cancer Matthias Eiber, Germany
09:45 – 10:05	Radiomolecular Theranostics: Future perspectives Richard P. Baum, Germany

SESSION II: A break-through in Education: ICPO Academy for Theranostics

10:05 – 10:20	ICPO Academy: Objectives, e-Learning Curriculum and Certification Elcin Zan, USA
10:20 – 10:35	ICPO Academy Pilot: Feedback from chinese clinicians Jingjing Zhang, Singapore
PANEL 10:35 – 11:00	How certified education improves patient access to Theranostics, the view of ICPO Academy Pillar Leaders Moderated by Francesco Giammarile, Austria and Gopinath Gnanasegaran, UK and joined by Vikas Prasad, USA; Thomas Beyer, Austria; Frank Rösch, Germany; Linda Gardner, USA and Josh Mailman, USA

11:00 – 11:30	Coffee Break (served in exhibition)
---------------	--



THURSDAY, 12 OCTOBER 2023

Collaborative efforts to greater patient access to Radio Theranostics

SESSION III: Greater patient access thanks to certified Centers initiatives

11:35 – 11:45	SNMMI Centers of Excellence Andrei Iagaru, USA
11:45 – 11:55	EANM Centers of Excellence Paola Erba, Italy
11:55 – 12:05	ENETS Centers of Excellence Nicola Fazio, Italy
12:05 – 12:15	ICPO Centers of Excellence Rodney Hicks, Australia
PANEL 12:15 – 12:40	How Centers of Excellence improve patient access to Theranostics Moderated by Richard P. Baum, Germany

12:45 – 13:45	Lunch served in the exhibition
13:00 – 13:30	Lunch Symposium → Page 12 Industry sponsored

SESSION IV: Radiomolecular Theranostics: Patients and referring physicians perspectives

13:45 – 13:55	Unmet needs for neuroendocrine patients: A global overview Josh Mailman, USA and Mark McDonnell, IRL
13:55 – 14:05	Radiomolecular Theranostics for prostate cancer patients in daily practice Jan Philipp Radtke, Germany
14:05 – 14:15	Radiomolecular Theranostics for NET patients in daily practice Christos Toumpanakis, United Kingdom
14:15 – 14:25	Key role of Multi Disciplinary Tumor Boards Marianne Pavel, Germany
PANEL 14:25 – 14:50	How to improve patient access and overall treatment outcomes? Moderated by Vikas Prasad, USA



THURSDAY, 12 OCTOBER 2023

Collaborative efforts to greater patient access to Radio Theranostics

SESSION V: Recent break-throughs and future developments from Industry

14:50 – 15:00	Partnering with pharma in RLT Jeevan Virk, Switzerland
15:00 – 15:10	Perspective from Bayer: Early research and clinical development activities Urs Hagemann, Germany
15:10 – 15:20	Perspective from Navigo: Innovations in Protein Engineering for Radiomolecular Theranostics applications Ulrich Haupts, Germany
15:20 – 15:30	Perspective from ArtBio Vicki Jardine, United Kingdom and Conrad Wüller, Austria
15:30 – 15:40	Perspective from Ariceum Therapeutics Greg Mullen, United Kingdom
15:40 – 16:10	Coffee Break (served in exhibition)

SESSION VI: Update on international Clinical Trials and Registries

16:10 – 16:20	Real World Data – Steps needed for making datamining more reliable and effective Vikas Prasad, USA
16:20 – 16:30	Expanding International Awareness & Education of Theranostic Trials Luke Nordquist, USA
16:30 – 16:40	NOBLE registry and RLT CONNECT platform for the donation of radiotherapeutics Alice Viana, Belgium
16:40 – 16:50	Using AI and Natural Language Processing to improve clinical trial discovery Josh Mailman, USA
PANEL 16:50 – 17:20	Keys to successful patient access and inclusion Moderated by Mark McDonnell, IRL
18:30	Bus transfer to Munich center for ICPO Forum Dinner attendees (prebooking required)
19:00	ICPO FORUM DINNER



FRIDAY, 13 OCTOBER 2023

Radiomolecular Theranostics innovation reaching the patients in need

08:00 – 08:30	Registration and Coffee
08:30 – 08:35	2nd Day Welcome by ICPO Foundation Odile Jaume, Germany

SESSION VII: Production and delivery: Radiomolecular Theranostics at the cross-roads

08:35 – 08:50	ITM: Meeting future demand by capacity expansion Neil Quigley, Germany
08:50 – 09:05	Curium: Future Alpha emitters – Which Ones Will Win? Roy Brown, USA
09:05 – 09:20	Monrol: How do we address challenges in the growing world of radioligand therapy? Aydin Kucuk, Turkey
09:20 – 09:35	New technical development for high output production Andreas Tuerler, Switzerland
09:35 – 09:50	Setting up a facility for the Early Supply and Commercial Supply of 225Ac Sven Van den Berghe, Belgium
PANEL 09:50 – 10:15	Demand and supply: How to match in the patient's interest? Moderated by Andrew Scott, Australia
10:15 - 10:45	Coffee Break (served in exhibition)

SESSION VIII: FAP Oncology and Beyond

Follow up of ICPO Theranostics FAP Summit November 2022

10:45 – 10:55	The Biology of Fibroblast Activating Protein and Its Importance in Oncology Peter Choyke, USA
10:55 – 11:05	FAP derivates from tumor microenvironment to Theranostics Tadashi Watabe, Japan
11:05 – 11:15	Oncology: FAP translation and clinical trials Frederik Giesel, Germany
11:15 – 11:25	FAP beyond Oncology: chronic diseases Martin Gotthardt, The Netherlands
PANEL 11:25 – 11:55	Has FAP already made it in clinical practice? Moderated by Elcin Zan, USA



FRIDAY, 13 OCTOBER 2023

Radiomolecular Theranostics innovation reaching the patients in need

SESSION IX: Focus on Alpha therapies

11:55 – 12:05	Clinical status of Alpha Emitters Oliver Sartor, USA
12:05 – 12:15	The Indian perspective to Ac-225, Pb-212 and other alphas Ishita Sen, India
12:15 – 12:25	Treating prostate cancer with Ac-PSMA pre or post castration/chemio Stuart More, South Africa
PANEL 12:25 – 12:55	Alphas challenger or alternative for betas? Moderated by Cristina Müller, Switzerland and Wolfgang Weber, Germany
12:55 – 13:15	Maurits Geerlings Award for Actinium 225 Advances – Award Ceremony presented by Mike Sathekge, South Africa and Richard Henkelmann, Germany
13:15 – 14:15	Lunch (served in exhibition)

SESSION X: Imaging instrumentation and best quality images for dosimetry

14:15 – 14:25	Instrumentation in Theranostics: Overview from a Clinician Standpoint Rodney Hicks, Australia
14:25 – 14:35	Total body PETCT Ivo Rausch, Austria
14:35 – 14:45	Whole body SPECTCT Ora Israel, Israel
PANEL 14:45 – 15:15	Instrumentation impact on patient journey and staff considerations Moderated by Thomas Beyer, Austria





FRIDAY, 13 OCTOBER 2023

Radiomolecular Theranostics innovation reaching the patients in need

SESSION XI: Ther-AI-nostics


15:15 – 15:25	AI in Theranostics tracer/target development Chris Behrenbruch, Australia
15:25 – 15:35	AI in patient workflow Antonis Kalemis, Germany
15:35 – 15:45	AI in patient diagnostic and prediction Kuangyu Shi, Switzerland
PANEL 15:45 – 16:15	Will AI help Radio Theranostics outperform amongst cancer therapies? Moderated by Lalith Kumar Shiyam Sundar, Austria and Abhinav Jha, USA

FINAL ROUNDTABLE

PANEL 16:15 – 16:55	A Special Outlook into Radiomolecular Theranostics Globally Moderated by Vikas Prasad, USA and Richard P. Baum, Germany joined by Paola Erba, Italy; Marianne Pavel, Germany; Ora Israel, Israel and Ishita Sen, India
16:55 – 17:00	Closing of the 3rd ICPO FORUM Odile Jaume, Germany

INDUSTRY & GENERAL INFORMATION





Targeting cancer

As a leading biotech company, we are developing a new generation of targeted cancer treatments. With our innovative radiodiagnostics and therapeutics, we are shaping the theranostics of tomorrow.



www.itm-radiopharma.com

itm
PASSION FOR PRECISION

NOVARTIS LUNCH TIME SYMPOSIUM

THURSDAY, 12 OCTOBER 2023 · 13:00 – 13:30, CET

Healthcare system Readiness for RLT is crucial and urgent to ensure equitable and timely access for patients across geographies. What are the key requirements and potential solutions and how partnerships can be a sustainable catalyst to achieve this

Time	Title	Host/Comments
13:00 – 13:03	Opening and introductions	Leonard Schaetz, Switzerland
13:03 – 13:08	Why HCS readiness is crucial and examples from SPARC Europe alliance; medical and EU level perspective	Nicola Fazio, Italy
13:08 – 13:13	JRC & EU Commission perspective and current initiatives towards RLT readiness	Uwe Holzwarth, Italy
13:13 – 13:18	Creating a ready health system for radioligand therapy; Policy action blueprints	Lucy Morgan, United Kingdom
13:18 – 13:23	Tackling HCS readiness for RLT; the industry perspective	Mart-Jan Blauwhoff, Germany
13:23 – 13:30	QA, next steps & closing remarks	All and Leonard Schaetz

LIST OF EXHIBITORS & SPONSORS

Gold Plus Sponsor

**ITM Isotope Technologies
Munich SE**



B1

Germany

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

www.itm-radiopharma.com

Gold Sponsor

Novartis Pharma AG



-

Switzerland

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.

© 2023 Novartis Pharma AG | CH-4002, Basel, Switzerland

Contact:

Novartis Pharma AG, Forum 1,
Novartis Campus, CH-4002, Basel,
Switzerland

Tel: +41 61 324 11 11

Email: infomed@adacap.com

www.novartis.com

LIST OF EXHIBITORS & SPONSORS

Silver Sponsor

Hermes Medical Solutions



A1

Sweden

Since its establishment in 1976 in Stockholm, Sweden, Hermes Medical Solutions has continuously innovated to enable faster and more personalized diagnosis and therapies in molecular imaging and theranostics. The company was the first to develop SPECT reconstruction software and dual-head whole-body scanning, and the first to introduce medical image fusion software for combined viewing of images from different scanners. We empower healthcare professionals by providing state-of-the-art software for all clinical scenarios in ONE vendor-neutral platform: Hermia. Our mission is to combine innovation leadership in nuclear medicine/molecular imaging software with customer-driven service, and our success lies in our close and longstanding collaboration with our customers to meet their software, support and service needs. The result is improved quality in patient management and decision support that benefits thousands of healthcare providers and their patients worldwide.

www.hermesmedical.com

Silver Sponsor

MONROL NUCLEAR PRODUCTS



A2

Turkey

Monrol is one of the world's largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today's nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 60 countries around the globe.

www.monrol.com

LIST OF EXHIBITORS & SPONSORS

Silver Sponsor

POINT Biopharma



–

United States

POINT Biopharma is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision medicine by combining a portfolio of targeted radioligand assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for medical isotopes including actinium-225 and lutetium-177. POINT's active clinical trials include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein- α (FAP- α), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment.

www.pointbiopharma.com

Silver Sponsor

Siemens Healthineers



A5

Germany

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients. Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world's most threatening diseases, improving the quality of outcomes, and enabling access to care. We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what's possible in healthcare to help improve people's lives around the world.

www.siemens-healthineers.com

LIST OF EXHIBITORS & SPONSORS

Silver Sponsor

Telix Pharmaceuticals



A4

Belgium

Telix is a global commercial-stage biopharmaceutical company focused on the development of therapeutic and diagnostic radiopharmaceuticals, and a service provider in nuclear medicine, with its European headquarters located in Liège, Belgium. Telix's targeted radiation imaging and therapy technologies have potential to transform the way clinicians can find and manage cancer and rare diseases, to inform treatment decisions and deliver personalised therapy in areas of major unmet medical need. With more than 20 clinical studies underway worldwide, Telix's core pipeline is focused on prostate, kidney, brain, and blood cancers as well as a range of hard to treat immunologic and rare diseases. Telix has received regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), Health Canada for its prostate cancer imaging agent (Ilucix[®], TLX591-CDx, kit for the preparation of ⁶⁸Ga-PSMA-11 injection) and is progressing marketing authorisation applications for TLX591-CDx in the EU and the UK.

www.telixpharma.com

Silver Sponsor

TRASIS



A3

Belgium

At Trasis we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster. To this end, we design, manufacture, sell and support high performance synthesizers (AllinOne and AllinOne mini), dose preparation equipment (Unidose and Quickfill dispensers), their shielding and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs. Our proven radiopharmaceutical expertise, coupled with our high-end instruments, allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization.

www.trasis.com

LIST OF EXHIBITORS & SPONSORS

Bronze Sponsor

Bayer AG



–

Germany

Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.

www.bayer.com

Bronze Sponsor

CheMatech



Village

France

CheMatech is a unique company in Europe specializing in the design and production of chelators (DOTA, NOTA derivatives) for Nuclear Medicine and Molecular Imaging. These molecules are used for the radiolabeling of bio-vectors such as peptides or antibodies. CheMatech provides its clients with a catalog of chelators suitable for most radiometals used for PET, SPECT or therapy and also offers custom syntheses, from the design of the chelator to the production in bulk. CheMatech is able to produce cGMP chelators, and related molecules, for the production of APIs from gram to kilogram scale.

www.chematech-mdt.com

LIST OF EXHIBITORS & SPONSORS

Bronze Sponsor

OncoBeta GmbH



Village

Germany

OncoBeta GmbH is an international medical device company specialized in innovative therapies for the treatment of non-melanoma skin cancer. Its flagship product, the Rhenium-SCT® (Skin Cancer Therapy), uses the radioactive isotope Rhenium-188 to precisely target NMSC while minimizing damage to healthy tissue. OncoBeta is dedicated to providing effective, non-invasive and painless treatments that improve quality of life.

www.oncobeta.com

Bronze Sponsor

PanTera



Village

Belgium

PanTera will allow cancer patients worldwide to benefit from Actinium-225 in therapeutic radiopharmaceuticals by making the radioisotope available in large quantities for approved drugs from 2028 onward, while supporting clinical trials and research by supplying small quantities of 225Ac from 2024 onward. The Early Supply will be assured on the basis of Thorium-229 decay and will allow to supply 1-2 Curies per year. Our industrial production process is based on transforming Radium-226 into high purity Actinium-225 by gamma irradiation and can provide >100Ci/y to the future market. In this way, PanTera supports development of the next generation cancer treatments, fostering a future where personalized nuclear medicine is the norm.

www.pantera-life.com

LIST OF EXHIBITORS & SPONSORS

Bronze Sponsor

Voximetry



Village

United States

Voximetry is a software and services company committed to advancing Dosimetry-Guided Radiopharmaceutical Therapy (DG-RPT). With Torch® we aim to improve patient outcomes by moving beyond population-based models and making it simpler for clinicians to develop patient-specific RPT treatment options. As the industry accuracy leader, Torch® provides the only GPU-accelerated full Monte Carlo Dose Calculation, including voxel-level corrections for density. The result is an extremely accurate dose assessment in seconds. Voximetry also offers a comprehensive range of Professional Services, with unmatched expertise and tools, which includes project management to expedite implementation and support for clinical trials, pre-clinical studies, and research.

www.voximetry.com

Basic Sponsor

ARTBIO INC



www.artbio.com

–

United States

Basic Sponsor

Curium



www.curiumpharma.com

–

France

Basic Sponsor

CMR



www.isotope-cmr.com

–

Germany

LIST OF EXHIBITORS & SPONSORS

Basic Sponsor

DSD Pharma GmbH



Village

Austria

DSD Pharma is a GDP-certified distributor of pharmaceuticals, radiopharmaceuticals and medical products, and medical-technical equipment in the field of nuclear medicine and radiopharmacy.

www.dsd-pharma.com

Basic Sponsor

Nuvia



www.sofie.com

–

France

Basic Sponsor

SOFIE



www.sofie.com

–

United States

LIST OF EXHIBITORS & SPONSORS

Basic Sponsor

The Oncidium foundation F.U.P.



Village

Belgium

The Oncidium foundation is dedicated to support and accelerate the development of radiotheranostics (RLT) for cancer care. Our activities are based on 3 pillars:

ACCESS through a wide network of ambassador experts and a worldwide map of therapy centers.

EDUCATION & awareness are essential, as they help to bring a better understanding of the functioning & benefits of RLT, still unknown to some practitioners & the general public.

HOPE – The foundation is evaluating all possibilities to support clinical developments of efficient RLT & individual cases to reduce treatment overall costs in low-income countries.
Come & meet us!

www.oncidiumfoundation.org

Basic Sponsor

WARMTH



Village

United States

The “World Association of Radiopharmaceutical and Molecular Therapy” (WARMTH) extends its activities worldwide. WARMTH is the only worldwide organization founded to promote the use of radionuclide molecular therapy and of the relatively novel paradigm of ‘Theranostics.’

WARMTH is a voluntary non-profit organization of individuals specifically associated for the purposes and for using the means, to achieve the following research and educational objectives: Join us in Muscat, Oman, for the 19th ICRT from the 8th to the 12th of February.


Come by our table to learn more about membership or to help us design a clinical trial finder tool for radiopharmaceutical trials.

www.warmth.org

LIST OF EXHIBITORS & SPONSORS


COMPANY NAME	SPONSOR	BOOTH NO	COUNTRY
ITM Isotope Technologies Munich SE	Gold Plus Sponsor	B1	Germany
Novartis Pharma AG	Gold Sponsor	–	Switzerland
Hermes Medical Solutions	Silver Sponsor	A1	Sweden
MONROL NUCLEAR PRODUCTS	Silver Sponsor	A2	Turkey
POINT Biopharma	Silver Sponsor	–	United States
Siemens Healthineers	Silver Sponsor	A5	Germany
Telix Pharmaceuticals	Silver Sponsor	A4	Belgium
TRASIS	Silver Sponsor	A3	Belgium
Bayer AG	Bronze Sponsor	–	Germany
ChemaTech	Bronze Sponsor	Village	France
OncoBeta GmbH	Bronze Sponsor	Village	Germany
PanTera	Bronze Sponsor	Village	Belgium
Voximetry	Bronze Sponsor	Village	United States
ARTBIO	Basic Sponsor	–	USA
Curium	Basic Sponsor	–	France
CMR	Basic Sponsor	–	Germany
DSD Pharma GmbH	Basic Sponsor	Village	Austria
Nuvia	Basic Sponsor	–	France
SOFIE	Basic Sponsor	–	United States
The Oncidium foundation F.U.P.	Basic Sponsor	Village	Belgium
WARMTH	Basic Sponsor	–	United States

FLOOR PLAN GROUND FLOOR



FLOOR PLAN

1ST FLOOR





Social Programme

ICPO FORUM Dinner

Thursday, 12 October 2023

€ 145,00

The Dinner will be held in one of the most traditional restaurant of Munich, the **Augustiner Stammhaus**. Located in the heart of the city it offers authentic, high class Bavarian food and its own brewed beer. The evening will be accompanied by a keynote from a physicist expert with a different perspective – and a touch of magic!

Don't miss out on this networking opportunity and secure your ticket.

The Social Programme has to be booked separate and is not included in the registration of the ICPO FORUM. Limited number of participants!



PETERS, SCHÖNBERGER & PARTNER

RECHTSANWÄLTE WIRTSCHAFTSPRÜFER STEUERBERATER

A special thanks to PETERS, SCHÖNBERGER & PARTNER mbB who are kindly sponsoring the appearance of our physicist expert.

FORUM General Information

VENUE

Science Congress Center Munich
Walther-von-Dyck-Straße 10
85748 Garching Munich, Germany

REGISTRATION

(in the foyer of the Science Congress Center)
Tel. +49(0)171 80 11 620

OPENING HOURS REGISTRATION

12. October 2023 07:15 – 17:30
13. October 2023 08:00 – 17:00

FORUM LANGUAGE

English is the official congress language. A simultaneous translation will not be available.

REGISTRATION FEES

ICPO FORUM	Early fee until 07 September	Standard fee from 08 September onwards
General Non-Member	€ 1.000,00	€ 1.250,00
General Member ¹	€ 800,00	€ 1.000,00
Academia ² Non-Member	€ 450,00	€ 600,00
Academia ² Member ¹	€ 360,00	€ 480,00

¹ To be entitled to register at a reduced member rate, you need to have a paid active membership in the ICPO Foundation before starting the registration process. Membership must be valid at the time of the ICPO FORUM. We reserve the right to change your registration category to Non-Member if the status of your membership is not up to date.

² Registration type Academia includes the following professionals who are not employed by industry: Physician; Scientist; Technologist; Laboratory Professional; Emeritus – Physician/Scientist; Emeritus – Technologist; Resident/Scientist In-Training/Student, Medical Student, Technologist Student

FORUM General Information

NAME BADGE

Upon arrival at the FORUM venue, all participants will receive a name badge, which must be worn visibly for the entire duration of the FORUM. The name badge acts as a personal entrance ticket for the FORUM and is non-transferable to other persons. In case of loss a reprint fee of 25% of the participation fee will be charged.

MEMBERSHIP

This program provides unique benefits to its future individual, corporate, and institutional members. Please find further information about the ICPO Membership Program [here](#).

CANCELLATION/NO-SHOW

Cancellations have to be submitted in writing to: icpo-forum@eurokongress.de. Cancellations received in writing up until Tuesday, 15 August 2023 incur a cancellation fee of EUR 65.00 (incl. VAT) for the FORUM Ticket. From this date onwards or in case of a no-show, registration fee reimbursements are no longer possible unless the organisers are provided with a named replacement who will take on the registration.

OPENING HOURS EXHIBITION

12 October 2023	07:15–17:30
13 October 2023	08:00–17:00

ICPO FORUM DINNER

The ICPO FORUM Dinner has to be booked separate and is not included in the registration of the ICPO FORUM. **Limited number of participants!**

Social Programme

ICPO FORUM Dinner Thursday, 12 October 2023	€ 145,00
---	----------

The ICPO FORUM Dinner will be held at one of the most traditional inns in the Bavarian capital: The Augustiner Original Building, in the middle of the pedestrian zone. Discover a piece of Munich's inn culture and let us spoil you with culinary delights.

FORUM General Information

RECORDINGS

All presentations and lectures are intellectual property of the authors and thus no audio or video shall be recorded or broadcasted at any time by the participants. In accordance with the authors the programme will be recorded by the organizers to be used for ICPO activities such as the Academy and the Centers projects, from knowledge sharing and promotion perspectives.

PHOTOGRAPHY AND FILMING ON SITE

There will be photography and filming at this event. The photographs and film footage will be published on the congress website or in congress-related print media. If you do not wish to be photographed and/or filmed at this event please contact the registration office.

DISCLAIMER

Neither the organiser nor ICPO Foundation shall be liable for accidents, bodily injury and theft as well as for additional costs due to the change of event date, location, programme or similar. Liability for additional costs due to delays, changes or cancellations of flights, trains or other means of transport as well as due to strike action, illness, weather or environmental disasters is also excluded. It is the responsibility of each participant to arrange appropriate theft, accident, health as well as travel cancellation insurance.

ORGANISATION UND INFORMATION

EUROKONGRESS

Congress + Event + Exhibition Management

Schleissheimer Straße 2, D-80333 München

Tel. +49 (0) 89-210 98 60, Fax +49 (0) 89-210 98 698

icpo-forum@eurokongress.de, www.eurokongress.de